The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Topical Ocular Drug Delivery: Recent Developments and Future Challenges
Abstract
Existing ocular drug delivery systems are fairly primitive and inefficient, but the stage is set for the rational design of newer and significantly improved systems. The focus of this review is on recent developments in topical ocular drug delivery systems relative to their success in overcoming the constraints imposed by the eye and to the improvements that have yet to be made. In addition, this review attempts to place in perspective the importance of pharmacokinetic modeling, ocular drug pharmacokinetic and bioavailability studies, and choice of animal models in the design and evaluation of these delivery systems. Five future challenges are perceived to confront the field. These are: (a) The extent to which the protective mechanisms of the eye can be safely altered to facilitate drug absorption, (b) Delivery of drugs to the posterior portion of the eye from topical dosing, (c) Topical delivery of macromolecular drugs including those derived from biotechnology, (d) Improved technology which will permit non-invasive monitoring of ocular drug movement, and (e) Predictive animal models in all phases of ocular drug evaluation. The design of ocular drug delivery systems is undergoing a gradual transition from an empirical to a rational base. This is partly due to a better understanding of the constraints on drug disposition in the eye and partly due to improved approaches in animal and clinical assessment of ocular drugs and drug delivery systems. Undoubtedly, interest in the broad area of ocular drug delivery has increased in recent years due to an increased understanding of a number of ocular physiological processes and pathological conditions, including aqueous humor dynamics, inflammation, corneal wound healing, and cataractogenesis, with a parallel increase in the number of drugs and drug candidates that have a beneficial effect in these conditions. Some of these compounds are rather potent and, at the same time, possess unfavorable aqueous solubility, stability, and lipophilicity characteristics. The inevitable result is that the formulation of these compounds for optimal topical delivery to the eye is increasingly challenging, much more so for the posterior than for the anterior portion of the eye. Coincidentally, the design of ocular drug delivery systems is becoming more sophisticated, partly due to a better understanding of the constraints in ocular drug disposition and partly due to the availability of polymers with a wide range of properties including biodegradability and bioadhesiveness. A number of recent reviews (1-5) have provided excellent background information on corneal drug transport mechanisms, ocular drug bioavailability, and ocular drug pharmacokinetics. Although a portion of each of these reviews also deals with the subject of ocular drug delivery, either directly or indirectly, a comprehensive current review of this subject does not appear to be available in the literature, hence the purpose of this article. Specifically, this paper will first review and describe (a) the constraints in topical ocular drug delivery, (b) mechanisms and constraints of ocular drug absorption, and (c) mathematics and modelling of ocular drug disposition in order to set the stage for understanding (a) the approaches that can be taken to optimize ocular drug delivery, (b) the suitability of rabbits as an animal model to evaluate ocular drug delivery systems, and (c) new challenges in ocular drug delivery system design. To provide a framework for subsequent discussions, it is useful to describe typical boundaries that are encountered in topical drug application. It is common to see approximately 1% or less of an applied dose absorbed across the cornea to reach anterior segment tissues of the eye. This, therefore, is an extremely inefficient process that also signals a substantial systemic drug load. Obviously, subsequent movement of this absorbed drug to the posterior segment of the eye will occur for only a tiny fraction of that which is in the anterior segment. In addition to the fraction of dose absorbed, the issue of residence time in the living eye is also important. Typically, an instilled aqueous solution will be eliminated from the precorneal area within 90 seconds. All things considered, improving the fraction of dose absorbed, achieving relatively high drug concentrations in the posterior segment, and maintaining drug in the front of the eye for several hours to several days are considerable challenges in ocular drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Holly, F. J., & Lemp, M. A. (1977) · Survey of Ophthalmology · doi:10.1016/0039-6257(77)90087-x · Cited by 559
Corneal Penetration Behavior of β-Blocking Agents I: Physicochemical Factors
Huang, H.-S., & Schoenwald, R. D. (1983) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600721108 · Cited by 422
Bioadhesive polymers as platforms for oral-controlled drug delivery: method to study bioadhesion
Park, K., & Robinson, J. R. (1984) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(84)90154-6 · Cited by 420
Self-citationOphthalmic drug delivery systems
Shell, J. W. (1984) · Survey of Ophthalmology · doi:10.1016/0039-6257(84)90168-1 · Cited by 291
Drop Size and Initial Dosing Frequency Problems of Topically Applied Ophthalmic Drugs
Chrai, S. S., Makoid, M. C., Eriksen, S. P., & Robinson, J. R. (1974) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600630304 · Cited by 254
Self-citationMechanistic and Quantitative Evaluation of Precorneal Pilocarpine Disposition in Albino Rabbits
Lee, V. H.-L., & Robinson, J. R. (1979) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600680606 · Cited by 230
Self-citationStudies on the mechanism of drug-binding to melanin
Larsson, B., & Tjälve, H. (1979) · Biochemical Pharmacology · doi:10.1016/0006-2952(79)90326-5 · Cited by 228
Effect of poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits
Miller, S. C., & Donovan, M. D. (1982) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(82)90114-4 · Cited by 210
Transport processes across the rabbit corneal epithelium: a review
Klyce, S. D., & Crosson, C. E. (1985) · Current Eye Research · doi:10.3109/02713688509025145 · Cited by 185
Maren, T. H., Jankowska, L., Sanyal, G., & Edelhauser, H. F. (1983) · Experimental Eye Research · doi:10.1016/0014-4835(83)90041-6 · Cited by 158
Penetration Routes of Topically Applied Eye Medications
Doane, M. G., Jensen, A. D., & Dohlman, C. H. (1978) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)77735-9 · Cited by 158
Schoenwald, R. D., & Ward, R. L. (1978) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600670614 · Cited by 152
Mechanistic Studies on Transcorneal Permeation of Pilocarpine
Sieg, J. W., & Robinson, J. R. (1976) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600651230 · Cited by 150
Self-citationNishida, T. (1983) · Archives of Ophthalmology · doi:10.1001/archopht.1983.01040020048007 · Cited by 138
Ocular drug bioavailability from topically applied liposomes
Lee, V. H. L., Urrea, P. T., Smith, R. E., & Schanzlin, D. J. (1985) · Survey of Ophthalmology · doi:10.1016/0039-6257(85)90109-2 · Cited by 81
Self-citationPilocarpine dispensation for the soft hydrophilic contact lens.
Ruben, M., & Watkins, R. (1975) · British Journal of Ophthalmology · doi:10.1136/bjo.59.8.455 · Cited by 75
Local Cyclosporine Therapy for Experimental Autoimmune Uveitis in Rats
Nussenblatt, R. B., Dinning, W. J., Fujikawa, L. S., et al. (1985) · Archives of Ophthalmology · doi:10.1001/archopht.1985.01050100135035 · Cited by 68
Topical carbonic anhydrase inhibitors
Schoenwald, R. D., Eller, M. G., Dixson, J. A., & Barfknecht, C. F. (1984) · Journal of Medicinal Chemistry · doi:10.1021/jm00372a020 · Cited by 65
Topically Applied Steroids in Corneal Disease
Cox, W. V. (1972) · Archives of Ophthalmology · doi:10.1001/archopht.1972.01000030310017 · Cited by 65
Effect of ocular pigmentation on pilocarpine pharmacology in the rabbit eye. II. Drug response
Urtti, A. O., Salminen, L., Kujari, H. P., & Jäntti, V. (1984) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(84)90132-7 · Cited by 48
Ethoxzolamide Analogue Gel: A Topical Carbonic Anhydrase Inhibitor
Lewis, R. A., Schoenwald, R. D., Eller, M. G., Barfknecht, C. F., & Phelps, C. D. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040031479027 · Cited by 46
Conrad, J. M., & Robinson, J. R. (1980) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600690806 · Cited by 41
Self-citationNishida, T., Tanaka, H., Nakagawa, S., Sasabe, T., Awata, T., & Manabe, R. (1984) · PubMed · Cited by 39
Retinol receptors in corneal epithelium, stroma and endothelium
Wiggert, B. O., Bergsma, D. R., Helmsen, R. J., Alligood, J. P., Lewis, M. S., & Chader, G. J. (1977) · Biochimica et Biophysica Acta (BBA) - Protein Structure · doi:10.1016/0005-2795(77)90045-9 · Cited by 34
FIBRONECTIN EYEDROPS FOR TRAUMATIC RECURRENT CORNEAL EROSION
Nishida, T., Nakagawa, S., Awata, T., et al. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90556-1 · Cited by 31
Systemic Absorption of Δ9-Tetrahydrocannabinol after Ophthalmic Administration to the Rabbit
Chiang, C.-W. N., Barnett, G., & Brine, D. R. (1983) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600720210 · Cited by 26
PHAGOCYTOSIS OF LATEX MICROSPHERES BY THE EPITHELIAL CELLS OF THE GUINEA PIG CONJUNCTIVA
LATKOVIC, S., & NILSSON, S. E. G. (1979) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.1979.tb00505.x · Cited by 22
Aminopeptidase Activity in Albino Rabbit Extraocular Tissues Relative to the Small Intestine
Stratford, R. E., & Lee, V. H. L. (1985) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600740707 · Cited by 20
Self-citationDuzman, E., QUINN, C. A., Warman, A. G., & Warman, R. (1982) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.1982.tb00608.x · Cited by 8
Cited by
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
The use of mucoadhesive polymers in ocular drug delivery
LUDWIG, A. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.07.005 · Cited by 922
Cyclodextrins: structure, physicochemical properties and pharmaceutical applications
Jansook, P., Ogawa, N., & Loftsson, T. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.11.018 · Cited by 811
Recent Perspectives in Ocular Drug Delivery
Gaudana, R., Jwala, J., Boddu, S. H. S., & Mitra, A. K. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9694-0 · Cited by 605
Mandal, A., Bisht, R., Rupenthal, I. D., & Mitra, A. K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.012 · Cited by 481
Metadata
- Authors
- LEE, V. H. L., & ROBINSON, J. R.
- Venue
- Journal of Ocular Pharmacology and Therapeutics
- Publisher
- SAGE Publications
- Published
- 1986-01
- Volume
- 2
- Issue
- 1
- Pages
- 67-108
- ISSN
- 1080-7683 (ISSN-L)
- 1557-7732
- OpenAlex
- W1985933245
- Cited by
- 503
- References
- 29
- FWCI
- 9.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.